DefiniGEN

DefiniGEN is a game-changing company headquartered in Cambridge, UK, with a mission to navigate drug development programs through uncertain terrain, minimizing risk while reducing costs and paving the way for a more efficient and effective future in the field of drug discovery. Our technology is revolutionizing liver models for efficacy and toxicology screening, utilizing a platform that enables the large-scale generation of hepatocyte-like cells (HLCs) with functional relevance comparable to human primary cells. Our HLCs effectively simulate crucial aspects of disease pathophysiology across various liver conditions, providing a more accurate understanding for drug development. By integrating CRISPR/Cas9 technology, DefiniGEN replicates...

Induced pluripotent stem cells (ipsc),hepatocytes,pancreatic cells,disease modelling,drug discovery,toxicity testing,inherited metabolic diseases (imd),screening,crispr gene editing,hit-to-lead,donor variance panel,and intestinal organoids

Definigen operates in the Biotechnology research industry.

Definigen's revenue is 11m - 100m

Definigen has 11 - 50 employees.